Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 1.00 |
| ▸ | ESRRG | P62508 | 13/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | HTR6 | P50406 | 1/20 | 0.91 |
| ▸ | ESRRB | O95718 | 5/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | PLD2 | O14939 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.76 |
| ▸ | ESRRA | P11474 | 2/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Hydroxytormifene SCHEMBL906310 | 1.00 | ESR1 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| SCHEMBL30421012 | 1.00 | ESR1 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| 4-Hydroxytormifene SCHEMBL906309 | 1.00 | ESR1 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| Toremifene SCHEMBL1152000 | 0.95 | HTR6 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| Toremifene SCHEMBL906278 | 0.95 | HTR6 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| Toremifene SCHEMBL7465 | 0.95 | HTR6 (1.00) | ESR1ESRRGLMNAHTR6ESRRB | |
| SCHEMBL906277 | 0.95 | ESR1 (0.91) | ESR1ESRRGLMNAHTR6ESRRB | |
| SCHEMBL4873146 | 0.95 | ESR1 (0.91) | ESR1ESRRGLMNAHTR6ESRRB | |
| Toremifene SCHEMBL2223880 | 0.94 | HTR6 (0.97) | ESR1ESRRGLMNAHTR6ESRRB | |
| SCHEMBL9099800 | 0.91 | HTR6 (0.86) | ESR1ESRRGLMNAHTR6ESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| WO-2023075628-A1 | METHOD AND SYSTEM FOR AUTOMACTICALLY DETERMINING AN IDENTIFICATION THRESHOLD FOR BIOMETRIC SAMPLES IN AN ACCESS CONTROL SYSTEM | ПУБЛИЧНОЕ АКЦИОНЕРНОЕ ОБЩЕСТВО "СБЕРБАНК РОССИИ" | 2023-05-04 | — | — | WO | claimed |
| CN-114079440-A | Smooth and fast updating method, system, medium and device of filter array | 森兰信息科技（上海）有限公司 | 2022-02-22 | — | — | CN | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | disclosed |
| US-20250263468-A1 | BINDING MOLECULE HAVING NEUTRALIZING ACTIVITY AGAINST CORONAVIRUS SUPERFAMILY | CELLTRION, INC. (KR) | 2025-08-21 | — | — | US | disclosed |
| CN-120200966-A | HAVIP switching method and device, SDN controller and medium | 锐捷网络股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-12307274-B2 | Methods and systems for virtual top-of-rack implementation | VEGESNA SRINIVAS (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250041404-A1 | T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-12171203-B2 | Transgenic biosensor | NEMAMETRIX INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-12137140-B2 | Scale out storage platform having active failover | PURE STORAGE, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20100317635-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ENDORECHERCHE, INC. (CA) | 2010-12-16 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090176305-A1 | COMPOUNDS AND METHODS FOR TREATING BREAST CANCER AND OTHER DISEASES | CITY OF HOPE | 2009-07-09 | — | — | US | disclosed |
| US-20090176305-A1 | COMPOUNDS AND METHODS FOR TREATING BREAST CANCER AND OTHER DISEASES | CITY OF HOPE | 2009-07-09 | — | — | US | disclosed |
| US-7531578-B2 | Acetic acid 4-{1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester; estrogen related receptor (ERR beta or ERR gamma) antagonist; thirty times more effective than 4-hydroxytamoxifen | CITY OF HOPE (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531578-B2 | Acetic acid 4-{1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester; estrogen related receptor (ERR beta or ERR gamma) antagonist; thirty times more effective than 4-hydroxytamoxifen | CITY OF HOPE (US) | 2009-05-12 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-5491173-A | ESTROGENIC, ANTIESTROGENIC AGENTS, ANTITUMOR AGENTS | ORION-YHTYMA OY (FI) | 1996-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317635-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | SHBG, CYP19A1, KISS1R | ESR1 5/4885ESRRG 23/4885LMNA 3719/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | ESR1 1519/4885ESRRG 1076/4885LMNA 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.